SCHEMBL6441608

SCHEMBL6441608

Cc1ccc(COc2nc(N)nc(-c3ccccn3)c2C#N)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.41
ADORA1 P30542 4/20 0.41
FFAR1 O14842 3/20 0.39
MGMT P16455 1/20 0.38
PDE10A Q9Y233 1/20 0.37
GRM5 P41594 2/20 0.36
TLR7 Q9NYK1 2/20 0.36
SQOR Q9Y6N5 3/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443675 0.88 MGMT (0.48) ADORA2AADORA1FFAR1MGMTGRM5
SCHEMBL6444357 0.84 SQOR (0.37) ADORA2AADORA1FFAR1GRM5SQOR
SCHEMBL6443034 0.81 SQOR (0.41) ADORA2AADORA1SQORKDM4EGABRA1
SCHEMBL5046609 0.80 ADORA2A (0.50) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL7151940 0.78 SQOR (0.55) ADORA2AADORA1SQORKDM4EPIK3CD
3-Methylpyridine SCHEMBL7499123 0.78 SQOR (0.46) ADORA2AADORA1SQORKDM4EMEN1
SCHEMBL6442743 0.78 ADORA2A (0.35) ADORA2AADORA1PDE10AKDM4EMEN1
SCHEMBL6441352 0.78 ADORA2A (0.35) ADORA2AADORA1PDE10AKDM4EMEN1
SCHEMBL6442328 0.77 SQOR (0.39) ADORA2AADORA1MGMTSQORKDM4E
SCHEMBL6441414 0.77 MGMT (0.55) ADORA2AADORA1MGMTTLR7SQOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885FFAR1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.